Compare IAC/Interactivecorp (PPLI) vs 10X Genomics Inc (TXG) Price & Performance

PPLI trades at $38.38, down 1.56% in the last session, with a bearish technical signal but attractive valuation ratios including a P/E of 6.49 and P/B of 0.56. Recent Q2 2026 earnings beat expectations with EPS of $6.77, driven by gains from its MGM stake, though revenue declined to $2.39B in 2025. The company is focusing on monetizing non-core assets and capital allocation toward its media business and MGM holdings, as highlighted in recent conference presentations.

The outlook is mixed: strong analyst support with a $58.80 consensus price target and 69% buy ratings offers upside, but risks include volatile earnings, declining revenue trends, and a shareholder investigation. Investors should weigh the deep valuation discount against execution challenges in asset sales and digital growth.

TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.

The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.